AAAAAA
Results: 1-25/32
Authors:
He, H
Hirokawa, Y
Manser, E
Lim, L
Levitzki, A
Maruta, H
Citation: H. He et al., Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation, CANCER J, 7(3), 2001, pp. 191-202
Authors:
Ellis, AG
Nice, EC
Weinstock, J
Levitzki, A
Burgess, AW
Webster, LK
Citation: Ag. Ellis et al., High-performance liquid chromatographic analysis of the tyrphostin AG1478,a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma, J CHROMAT B, 754(1), 2001, pp. 193-199
Authors:
Fishbein, I
Chorny, M
Banai, S
Levitzki, A
Danenberg, HD
Gao, JC
Chen, X
Moerman, E
Gati, I
Goldwasser, V
Golomb, G
Citation: I. Fishbein et al., Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model, ART THROM V, 21(9), 2001, pp. 1434-1439
Authors:
Bonasera, TA
Ortu, G
Rozen, Y
Krais, R
Freedman, NMT
Chisin, R
Gazit, A
Levitzki, A
Mishani, E
Citation: Ta. Bonasera et al., Potential F-18-labeled biomarkers for epidermal growth factor receptor tyrosine kinase, NUCL MED BI, 28(4), 2001, pp. 359-374
Authors:
Garcia, R
Bowman, TL
Niu, GL
Yu, H
Minton, S
Muro-Cacho, CA
Cox, CE
Falcone, R
Fairclough, R
Parsons, S
Laudano, A
Gazit, A
Levitzki, A
Kraker, A
Jove, R
Citation: R. Garcia et al., Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells, ONCOGENE, 20(20), 2001, pp. 2499-2513
Authors:
Levitzki, A
Citation: A. Levitzki, Protein tyrosine kinase inhibitors as therapeutic agents, T CURR CHEM, 211, 2001, pp. 1-15
Authors:
Benhar, M
Dalyot, I
Engelberg, D
Levitzki, A
Citation: M. Benhar et al., Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress, MOL CELL B, 21(20), 2001, pp. 6913-6926
Authors:
Nagane, M
Narita, Y
Mishima, K
Levitzki, A
Burgess, AW
Cavenee, WK
Huang, HJS
Citation: M. Nagane et al., Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor, J NEUROSURG, 95(3), 2001, pp. 472-479
Authors:
He, H
Levitzki, A
Zhu, HJ
Walker, F
Burgess, A
Maruta, H
Citation: H. He et al., Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases, J BIOL CHEM, 276(29), 2001, pp. 26741-26744
Authors:
Bell, M
Capone, R
Pashtan, I
Levitzki, A
Engelberg, D
Citation: M. Bell et al., Isolation of hyperactive mutants of the MAPK p38/Hog1 that are independentof MAPK kinase activation, J BIOL CHEM, 276(27), 2001, pp. 25351-25358
Authors:
Levitzki, A
Citation: A. Levitzki, Quinoxalines versus indolinones as inhibitors of restenosis, CIRCUL RES, 88(12), 2001, pp. E77-E77
Authors:
Ben-Bassat, H
Levitzki, A
Citation: H. Ben-bassat et A. Levitzki, Inhibitors of tyrosine kinases in the treatment of psoriasis, ISR MED ASS, 2, 2000, pp. 69-73
Authors:
He, H
Hirokawa, Y
Levitzki, A
Maruta, H
Citation: H. He et al., An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: In vitro and in vivo studies, CANCER J, 6(4), 2000, pp. 243-248
Authors:
Fishbein, I
Waltenberger, J
Banai, S
Rabinovich, L
Chorny, M
Levitzki, A
Gazit, A
Huber, R
Mayr, U
Gertz, SD
Colomb, G
Citation: I. Fishbein et al., Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats, ART THROM V, 20(3), 2000, pp. 667-676
Authors:
Volberg, T
Bershadsky, AD
Elbaum, M
Gazit, A
Levitzki, A
Geiger, B
Citation: T. Volberg et al., Disruption of microtubules in living cells by tyrphostin AG-1714, CELL MOTIL, 45(3), 2000, pp. 223-234
Authors:
Klein, S
Reuveni, H
Levitzki, A
Citation: S. Klein et al., Signal transduction by a nondissociable heterotrimeric yeast G protein, P NAS US, 97(7), 2000, pp. 3219-3223
Authors:
Reuveni, H
Geiger, T
Geiger, B
Levitzki, A
Citation: H. Reuveni et al., Reversal of the Ras-induced transformed phenotype by HR12, a novel Ras farnesylation inhibitor, is mediated by the Mek/Erk pathway, J CELL BIOL, 151(6), 2000, pp. 1179-1192
Authors:
Zhang, Y
Turkson, J
Carter-Su, C
Smithgall, T
Levitzki, A
Kraker, A
Krolewski, JJ
Medveczky, P
Jove, R
Citation: Y. Zhang et al., Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity, J BIOL CHEM, 275(32), 2000, pp. 24935-24944
Authors:
Blum, G
Gazit, A
Levitzki, A
Citation: G. Blum et al., Substrate competitive inhibitors of IGF-1 receptor kinase, BIOCHEM, 39(51), 2000, pp. 15705-15712
Authors:
Levitzki, A
Citation: A. Levitzki, Protein tyrosine kinase inhibitors as novel therapeutic agents, CANC DRUG, 5, 2000, pp. 453-465
Authors:
Schindler, T
Sicheri, F
Pico, A
Gazit, A
Levitzki, A
Kuriyan, J
Citation: T. Schindler et al., Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor, MOL CELL, 3(5), 1999, pp. 639-648
Authors:
Catlett-Falcone, R
Landowski, TH
Oshiro, MM
Turkson, J
Levitzki, A
Savino, R
Ciliberto, G
Moscinski, L
Fernandez-Luna, JL
Nunez, G
Dalton, WS
Jove, R
Citation: R. Catlett-falcone et al., Constitutive activation of Stat3 signaling confers resistance to apoptosisin human U266 myeloma cells, IMMUNITY, 10(1), 1999, pp. 105-115
Authors:
Poradosu, E
Gazit, A
Reuveni, H
Levitzki, A
Citation: E. Poradosu et al., alpha-Cyanocinnamide derivatives: A new family of non-peptide, non-sulfhydryl inhibitors of Ras farnesylation, BIO MED CH, 7(8), 1999, pp. 1727-1736
Authors:
Karni, R
Jove, R
Levitzki, A
Citation: R. Karni et al., Inhibition of pp60(c-Src) reduces Bcl-X-L expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors, ONCOGENE, 18(33), 1999, pp. 4654-4662
Authors:
Levitzki, A
Citation: A. Levitzki, Protein tyrosine kinase inhibitors as novel therapeutic agents, PHARM THERA, 82(2-3), 1999, pp. 231-239